Browse our 650+ Publications
Latest Publications
Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
Sidana S, et al.
Blood
October 2024
Authors and Affiliates
Surbhi Sidana1*, Krina K. Patel2*, Lauren C. Peres*3, Radhika Bansal4, Mehmet H.
Kocoglu5, Leyla Shune6, Shebli Atrash7, Kinaya Smith8, Shonali Midha9, Christopher Ferreri,7,
Binod Dhakal8, Danai Dima10, Patrick Costello9, Charlotte Wagner11, Ran Reshef12, Hitomi
Hosoya1, Lekha Mikkilineni1, Djordje Atanackovic5, Saurabh Chhabra13, Ricardo Parrondo14,
Omar Nadeem9, Hashim Mann,15 Nilesh Kalariya2, Vanna Hovanky1, Gabriel De Avila3, Ciara L
Freeman3, Frederick L. Locke3, Melissa Alsina3, Sandy Wong16, Megan Herr17, Myo Htut18,
Joseph McGuirk6, Douglas W. Sborov11, Jack Khouri10, Thomas Martin16, Murali Janakiram18*, Yi
Lin4*, and Doris K. Hansen3*
*S.S, K.K.P, L.C.P are co-first authors; M.J, Y.L, and D.K.H are co-senior authors.
Affiliations: 1. Stanford University School of Medicine 2. The University of Texas MD Anderson
Cancer Center, 3. Moffitt Cancer Center, 4. Mayo Clinic, Rochester, 5. University of Maryland
School of Medicine, 6. University of Kansas Medical Center, 7. Levine Cancer Institute, 8.
Medical College of Wisconsin, 9. Dana-Farber Cancer Institute, 10. Cleveland Clinic Taussig
Cancer Center. 11. Huntsman Cancer Institute at the University of Utah, 12. Columbia
University Irving Medical Center, 13. Division of Hematology/Oncology, Department of Medicine,
Mayo Clinic, Phoenix, Arizona, 14. Mayo Clinic, Jacksonville 15. Virginia Commonwealth
University, 16. University of California San Francisco, 17. Rosewell Park Cancer Center, 18.
City of Hope Comprehensive Cancer Center,
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Badros A, et al.
Blood
September 2024
Authors and Affiliates
Ashraf Badros,1 Laahn Foster,2 Larry D. Anderson Jr,3 Chakra P. Chaulagain,4 Erin Pettijohn,5
Andrew J. Cowan,6 Caitlin Costello,7 Sarah Larson,8 Douglas W. Sborov,9 Kenneth H. Shain,10
Rebecca Silbermann,11 Nina Shah,12* Alfred Chung,12 Maria Krevvata,13 Huiling Pei,14 Sharmila
Patel,15 Vipin Khare,15 Annelore Cortoos,15 Robin Carson,13 Thomas S. Lin,15 and Peter
Voorhees16
1Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, United
States; 2Division of Hematology Oncology, University of Virginia, Charlottesville, VA, United
States; 3Myeloma, Waldenstrom’s and Amyloidosis Program, Simmons Comprehensive Cancer
Center, UT Southwestern Medical Center, Dallas, TX, United States; 4Department of
Hematology and Oncology, Myeloma and Amyloidosis Program, Cleveland Clinic Florida,
Weston, FL, United States; 5Cancer and Hematology Centers of Western Michigan, Grand
Rapids, MI, United States; 6Division of Medical Oncology, Fred Hutch Cancer Center/University
of Washington, Seattle, WA, United States; 7Moores Cancer Center, University of California San
Diego, La Jolla, CA, United States; 8Division of Hematology and Oncology, David Geffen
School of Medicine at UCLA, Los Angeles, CA, United States; 9Huntsman Cancer Institute,
University of Utah, Salt Lake City, UT, United States; 10Department of Malignant Hematology,
H. Lee Moffitt Cancer Center, Tampa, FL, United States; 11Knight Cancer Institute, Oregon
Health & Science University, Portland, OR, United States; 12Department of Medicine, University
of California San Francisco, San Francisco, CA, United States; 13Janssen Research &
Development, LLC, Spring House, PA, United States; 14Janssen Research & Development, LLC,
Titusville, NJ, United States; 15Janssen Scientific Affairs, LLC, a Johnson & Johnson company,
Horsham, PA, United States; 16Levine Cancer Institute, Atrium Health Wake Forest University
School of Medicine, Charlotte, NC, United States.
Epcoritamab in relapsed/refractory large B-cell lymphoma:2-year follow-up from the pivotal EPCORE NHL-1 trial
Thieblemont C, et al.
Leukemia
September 2024
Authors and Affiliates
Catherine Thieblemont 1✉, Yasmin H. Karimi2, Herve Ghesquieres3, Chan Y. Cheah4, Michael Roost Clausen5, David Cunningham6,
Wojciech Jurczak 7, Young Rok Do8, Robin Gasiorowski 9, David John Lewis10, Tae Min Kim 11, Marjolein van der Poel12,
Michelle Limei Poon13, Tatyana Feldman14, Kim M. Linton15, Anna Sureda 16, Martin Hutchings17, Minh H. Dinh 18, Nurgul Kilavuz19,
David Soong19, Thomas Mark20, Mariana Sacchi19, Tycel Phillips21,23 and Pieternella J. Lugtenburg22
1Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France. 2Division of Hematology/Oncology, University of
Michigan, Ann Arbor, MI, USA. 3Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France. 4Sir Charles Gairdner Hospital and the University of Western Australia,
Nedlands, Australia. 5Vejle Hospital, Vejle, Denmark. 6The Royal Marsden NHS Foundation Trust, Sutton, UK. 7MSC National Research Institute of Oncology, Kraków, Poland.
8Keimyung University Dongsan Medical Center, Daegu, Republic of Korea. 9Concord Hospital, University of Sydney, Sydney, Australia. 10University Hospitals Plymouth NHS Trust,
Derriford Hospital, Plymouth, UK. 11Seoul National University Hospital, Seoul, Republic of Korea. 12Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Maastricht,
Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The
Netherlands. 13National University Hospital, Singapore, Singapore. 14John Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine,
Hackensack, NJ, USA. 15The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK.
16Clinical Hematology Department, Institut Català d’Oncologia – L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain. 17Rigshospitalet and University of Copenhagen,
Copenhagen, Denmark. 18AbbVie, North Chicago, IL, USA. 19Genmab, Plainsboro, NJ, USA. 20Genmab, Copenhagen, Denmark. 21University of Michigan Comprehensive Cancer
Center, Ann Arbor, MI, USA. 22Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology, University Medical Center,
Rotterdam, The Netherlands. 23Present address: City of Hope, Duarte, CA, USA. ✉email: catherine.thieblemont@aphp.fr
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma(MOLTO): a multicentre, single-arm, phase 2 trial
Tedeschi A, et al.
Lancet Oncology
September 2024
Authors and Affiliates
Alessandra Tedeschi*, Anna Maria Frustaci*, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani, Marina Motta,
Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Gioacchino Catania, Marina Deodato, Rebecca Jones, Valentina Tabanelli, Valentina Griggio,
Georg Stüssi, Angelica Calleri, Katia Pini, Roberto Cairoli, Thorsten Zenz, Alessio Signori, Emanuele Zucca, Davide Rossi, Marco Montillo
Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy (A Tedeschi MD, A M Frustaci MD, M Deodato MD, R Cairoli MD, M Montillo MD);
Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland (A Condoluci MD, Prof D Rossi MD, K Pini BS, Prof E Zucca MD); Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero
Cantonale, Bellinzona, Switzerland (A Condoluci, Prof D Rossi, Prof G Stüssi MD, Prof E Zucca MD); University Division of Hematology, AOU Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy (R Jones MD, V Griggio PhD); Department of Oncology ASST Sette Laghi,\ Ospedale di Circolo, Varese, Italy (Prof M Coscia MD);Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy (Prof R Chiarle MD, V Tabanelli MD, A Calleri PhD); Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy (Prof R Chiarle); Department of Pathology, Boston Children’s Hospital, Boston, MA, USA (Prof R Chiarle); Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “L e A Seràgnoli”, Bologna, Italy
Longitudinal study of immunity to SARS-CoV2 inocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination
Kister I., et al.
Annals of Clinical and Translational Neurology
August 2024
Authors and Affiliates
Ilya Kister, Ryan Curtin, Amanda L. Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E. Bacon, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie,
Sean Selva, Marie I. Samanovic, Mark J. Mulligan, Yury Patskovsky, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Michelle Krogsgaard & Gregg J. Silverman
Case report of fatal immune-mediatedmyocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependentCD28 costimulator and dualPD-L1/CTLA-4checkpoint inhibitor, incombination with pembrolizumab
Cavalcante L., et al.
Journal for ImmunoTherapy of Cancer
August 2024
Authors and Affiliates
Ludimila Cavalcante, Sreenivasa Chandana, Nehal Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar.
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
Touzeau C, et al.
Blood
August 2024
Authors and Affiliates
Cyrille Touzeau (University hospital, France) Amrita Krishnan (City of Hope Comprehensive Cancer
Center, United States) Philippe Moreau (Hematology, University Hospital Hôtel-Dieu, France) Aurore
Perrot (CHU Toulouse - IUCT Oncopole, France) Saad Usmani (Memorial Sloan Kettering Cancer Center,
United States) Salomon Manier (CHU Lille, France) Michele Cavo (Seràgnoli Institute of Hematology;
Bologna University School of Medicine, Bologna, Italy, Italy) Carmen Martinez Chamorro (Hospital
Universitario Quirón Pozuelo, Spain) Ajay Nooka (Emory University Winship Cancer Institute, United
States) Thomas Martin (UCSF, United States) Lionel Karlin (Hôpital Lyon Sud, France) Xavier Leleu
(Hopital La Miletrie, France) Nizar Bahlis (Arnie Charbonneau Cancer Institute, University of
Calgary, Canada) Britta Besemer (University Hospital of Tuebingen, Germany) Lixia Pei (Janssen R&D,
United States) Sarah Stein (Janssen R&D US, United States) Shun Xin Wang Lin (Janssen Research &
Development, United States) Danielle Trancucci (Janssen Research & Development, United States)
Raluca Verona (Janssen Research & Development, United States) Suzette Girgis (Janssen Research &
Development, LLC, United States) Xin Miao (Janssen Research & Development, LLC, United States)
Clarissa Uhlar (Janssen R&D, United States) Katherine Chastain (Janssen Research & Development,
LLC, United States) Alfred Garfall (University of Pennsylvania, United States)
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence
Martinez-Lopez J, et al.
Blood Cancer Journal
August 2024
Authors and Affiliates
J. Martinez-Lopez 1,2, N. Lopez-Muñoz 1, A. Chari 2, S. Dorado 3, S. Barrio1, S. Arora2, A. Kumar2, A. Chung2, T. Martin 2 and
J. Wolf2
1Hematology Department, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain. 2Department of Medicine, University of California San Francisco, San Francisco,
CA, USA. 3Medical Department, Altum Sequencing, Madrid, Spain.
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha A, et al.
Cancer
August 2024
Authors and Affiliates
Attaya Suvannasankha MD1 | Nizar Bahlis MD2 | Suzanne Trudel MSc, MD3 |
Katja Weisel MD4 | Christian Koenecke MD5 | Albert Oriol MD, PhD6 |
Peter M. Voorhees MD7 | Aranzazu A. Alonso MD8 | Natalie S. Callander MD9 |
María‐Victoria Mateos MD, PhD10 | Nishitha Reddy MD11 | Shawn Hakim PhD12 |
John LaMacchia MD, PhD13 | Nashita Patel MSc, PhD14 | Danaé Williams MSc12 |
Roxanne C. Jewell PhD15 | Xiangdong Zhou PhD12 | Ira Gupta MD16 |
Joanna Opalinska MD12 | Ajay K. Nooka MD, MPH, FACP17
1
Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, Indiana, USA
2
Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada
3
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4
University Medical Center Hamburg‐Eppendorf, Hamburg, Germany
5
Hannover Medical School, Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany
6
Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
7
Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA
8
Hospital Universitario Quirónsalud Madrid, Madrid, Spain
9
Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA
10Instituto de Investigación Biomédica de Salamanca and Centro de Investigación del Cáncer, Hospital Universitario de Salamanca, Salamanca, Spain
11Merck & Co., Inc, Rahway, New Jersey, USA
12GlaxoSmithKline, Upper Providence, Pennsylvania, USA
13GlaxoSmithKline, Waltham, Massachusetts, USA
14GlaxoSmithKline, Stevenage, UK
15GlaxoSmithKline, Durham, North Carolina, USA
16GlaxoSmithKline, Philadelphia, Pennsylvania, USA
17Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia, USA